Contribution of the immune system to HIV persistence Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine,

Slides:



Advertisements
Similar presentations
2014 “Towards an HIV Cure” symposium Melbourne Genetically Characterizing the Role of Cell Proliferation in Maintaining Persistent HIV during Effective.
Advertisements

Evaluation of Human Thymic Function during Health and HIV-1 Infection
New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.
Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
Measuring the latent HIV Reservoir
2014 “Towards an HIV Cure” symposium Melbourne Following in vitro culture with myeloid dendritic cells, negative regulators of T cell activation are expressed.
Unique integration patterns in an in vitro model of HIV-1 latency. Suha M. Saleh, Dimitrios Vatakis, Andrew Harman, Anthony Cunningham, Paul U. Cameron,
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
Track A Report Guido Poli Vita-Salute San Raffaele University & Scientific Institute, Milano, Italy XVIII International AIDS Conference, Vienna, 2010.
Main questions on HIV persistence and on obstacles to HIV eradication Jean-Pierre Routy M.D. McGill University Montreal Toward an HIV cure: Insight into.
Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.
1111 Glut1: establishing a new paradigm for HIV-1 infection by regulating glucose metabolism and activation in CD4+ T cells in HIV-1-positive subjects.
Lecture 8 The Development of Lymphocytes. Core content.
Memory CCR6+CD4+ T-Cells are Selectively Imprinted with a Transcriptional Program Favorable to Productive HIV-1 Infection Patricia Monteiro, Jean-Philippe.
Myeloid dendritic cells and HIV latency in resting T-cells Nitasha A Kumar, Vanessa A Evans, Suha Saleh, Candida de Fonseca Pereira, Paula Ellenberg, Paul.
Lecture: HIV I.Motivation What can we learn when we apply evolutionary principles to our understanding of the of the HIV epidemic?? Can we use HIV to introduce.
Alternative RNA splicing in latently infected T cells generates chimeric cellular:HIV mRNAs with the potential to generate Tat and reactivate infection.
2014 “Towards an HIV Cure” symposium Melbourne A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-nai ̈ ve individuals.
Measuring the latent HIV Reservoir
Hematopoietic stem cell based gene therapy for HIV diseases
2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.
Introduction to Autoimmunity Alon Monsonego, Ph.D. The department of Microbiology and Immunology Tel:
Treg exert differential effects on the proliferation and differentiation of CD8 T cell subsets in chronic HIV-1 infection M. Nikolova 1, M. Muhtarova 1,
Design of immune system Immune system Self/non-self recognition The state of protection from infectious disease 自我非我 Memory Acceptance vs rejection 疫苗.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
The role of PI3K signaling pathways in HIV-1 infection of resting CD4+T-cells Suha Saleh, Paul Cameron, Georgina Sallmann, Anthony Jaworowski, and Sharon.
Future directions in HIV basic science research The hunt for a cure.
Concepts in Basic Science and Translational Research
Latent infection and cellular reservoirs
Novel Approaches: Treatment and HIV Pathogenesis L. Trautmann, Ph.D. VGTI Florida.
Evaluation of residual HIV-1 replication among individuals receiving different antiretroviral treatment regimens Giron, LB; Tenore, S; Gabriel, R; Janini,
Viral Tissue Reservoirs Are Determined Early and Little Viral RNA Is Detected during Suppression in the Macaque Model Zandrea Ambrose, Ph.D. Division of.
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Part IV The adaptive immune response Chapter 9
Are we most likely to cure HIV with gene therapy? Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine,
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
Learning About an HIV Cure by Doing Studies in HIV+ Subjects Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University.
Myeloid dendritic cells induce HIV-1 latency in non- proliferating CD4 + T cells IAS WORKSHOP, 16 & 17 JULY 2010.
Pathogenesis of HIV-hepatitis B co-infection Sharon R Lewin, FRACP, PhD Infectious Diseases Unit, Alfred Hospital Department of Medicine, Monash University.
Germline-encoded receptors Gene rearranged receptors: TCR/BCR Ags………. Innate immunity Adaptive immunity B/T cells Pattern recognition Epitope recognition.
MICR 304 Immunology & Serology Lecture 6 NK Cells, Lymphocytes Chapter 1.4 –1.17; 2.30 – 2.33 Lecture 6 NK Cells, Lymphocytes Chapter 1.4 –1.17; 2.30 –
T-CELL MEMORY Central Effector. 1781:Measles epidemic in the Faroe Islands No measles for 65 years 1846: Measles epidemic Those individuals, who were.
HIV: Science, Sex and Society. Lecture 2. Strategies for the cure of HIV-1. Mario Stevenson, Ph.D Department of Medicine.
1 Circulating T cells Ag in the Inflammatory tissue Ch 9 T Cell-Mediated Immunity Ag-specific T cell response.
Title Box. “Towards an HIV Cure”: Presentation Outline -Why do we need a cure? -Is a cure feasible and what type of cure can we reach? -Why does HAART.
___________DEFENSES of the HOST: THE IMMUNE RESPONSE
IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.
HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.
The Future of HIV/AIDS: The Road to a Cure. How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun,
NAJRAN UNIVERSITY College of Medicine NAJRAN UNIVERSITY College of Medicine Microbiology &Immunology Course Lecture No. 15 Microbiology &Immunology Course.
2014 “Towards an HIV Cure” symposium Melbourne An Overview of HIV Cure Research in 2014 Diana Finzi, Ph.D. Director, Basic Science Program Division of.
Background  HIV-1 infection persists in reservoirs and leads to progressive depletion of CD4+ T-cells even in subjects with slow disease progression 
Davey Smith, MD Professor of Medicine University of California San Diego La Jolla, California When Will It All Be Over? HIV Cure Efforts Los Angeles, California:
T-CELL MEMORY Central Effector.
 Gram-positive cocci in chains  Hemolytic exotoxin  Capsule  Serogroup based on M antigen  Group A:  Pharyngitis  Scarlet fever  Necrotizing fascitis.
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
State of HIV Cure Research
M1 – Immunology CYTOKINES AND CHEMOKINES March 26, 2009 Ronald B
HIV Cure: Current Status and Future Perspectives
Thymocyte development summary
HEATHER Feedback Meeting
Immunodeficiency (2 of 2)
Toward A Cure for HIV Plenary Lunch
The block-and-lock approach
Differentiation and Functions of CD8+ Effector T Cells
Why we should ‘shock and kill’
HCV treatment with direct-acting antivirals (DAAs) in HIV/HCV coinfected subjects affects the dynamics of the HIV-1 reservoir Y. Ghiglione1, M.L. Polo1,
Immunodeficiency (2 of 2)
Immunologic strategies for HIV-1 remission and eradication
Presentation transcript:

Contribution of the immune system to HIV persistence Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine, Monash University Co-head, Centre for Virology, Burnet Institute, Melbourne, Australia Towards an HIV Cure, 5 th IAS Conference, Rome, 2011

Outline  Establishing HIV latency –Where and how are resting T-cells infected? –Chemokines –Dendritic cells  Maintaining HIV latency –Homeostatic proliferation –Inflammation  Role of the adaptive immune response  Relevance to strategies for cure

establishing HIV latency

Latent infection can be established in many T cells ThymusPeripheral circulation MM M M Effector/ transitional Central memory Ag Central memory Bone marrow Chun et al., Nature 1997; 387:183; Finzi et al., Science 1997; 278:1295; Brooks et al., Nat Med 2001; 7:459 ; Chomont et al., Nat Med 2009; 15: 893; Dai et al., J Virol 2009: 83(9): ; Carter et al., Nat Med 2010; 16: 446; Wightman et al., J Infect Dis 2010; 202(11): Naïve T cellsTransitional memory Multipotent progenitor cells Latent reservoir Naive

The main reservoir is central and transitional memory T-cells Chomont et al., Nature Med 2009;15: 893

GI tract is enriched for latently infected cells Chun et al., J Infect Dis 2008; 197:714; Yukl et al., J Infect Dis 2010; 202(10): N=8, time on HAART with undetectable HIV RNA 2.8 – 12 years HIV DNA Copies per million cells

Most latently infected and productively infected cells are in lymphoid tissue North et al., J Virol 2010; 84(6): Mmu VL=17 CSF VL<50 DNARNA Lymphoid tissue GI tract+++ CNSNeg/+Neg Reproductive tissue +Neg Other+Neg RT-SHIV infection HAART =Tenofovir/emtricitabine/efavirenz

Size of HIV Reservoir correlates with activated CD8+ T cells (in Sigmoid Colon) Seth et al., Mucosal Immunology 2008:1:

What is unique about these tissue sites?  Ongoing replication due to –Poor penetration of drugs? –Localised sites of inflammation?  Unique long-lived cells such as macrophages or DCs allowing for cell-cell transmission?  Infection of resting cells?

Unactivated resting cells Resting CD4+ T-cell Ex vivo tissue blocks Eckstein et al, Immunity 2001; 15: 671; Kreisberg et al., J Exp Med 2006; 203:865; Infection of resting T-cells in vitro chemokines In vitro Saleh et al., Blood 2007; 110:416; Cameron et al., Proc Natl Acad Sci 2010 epub Sept 18

Multiple chemokines can induce latent HIV infection in resting CD4+ T cells. Cameron et al., Proc Natl Acad Sci 2010; 107(39):

Chemokine receptor ligation activates cofilin and actin polymerisation CXCR4 + gp120 CCR7 + CCL19 Yoder et al Cell 2008 Cameron et al PNAS 2010

Chemokine signalling pathways PI3K PI3K

Inhibition of Erk1/2, Jnk and NF-kB eliminates integration (ALu-LTR) SC-514 Bay SP SB PD CCL19+DMSO JNKERK NF  B P38 Saleh et al., 5 th IAS Conference, Rome, 2011

Unactivated resting cells Resting CD4+ T-cell Ex vivo tissue blocks Eckstein et al, Immunity 2001; 15: 671; Kreisberg et al., J Exp Med 2006; 203:865; Infection of resting T-cells in vitro chemokines In vitro Saleh et al., Blood 2007; 110:416; Cameron et al., Proc Natl Acad Sci 2010 epub Sept 18 Dendritic cells

Dendritic cells facilitate latent HIV infection Evans et al., unpublished

maintenance of HIV latency

What is the fate of a latently infected cell? Negative regulators differentiation EM activation Homeostatic proliferation

Number of latently infected cells is correlated with proliferation: role of IL-7 Chomont et al., Nat Med 2009

IL-7 increases proliferation leading to expansion of HIV DNA in vivo HIV infected subjects under suppressive HAART received IL-7 injections (ACTG5214, blind study). Vandergreeten 6 th IAS conference on HIV Pathogenesis, Treatment and Prevention, Rome, 2011 Day 0Day p=0.03 Int HIV DNA per mL of blood Day 0Day Int HIV DNA per 10 6 CD4 T cells

What is the fate of a latently infected cell? Negative regulators differentiation EM activation Homeostatic proliferation

PD-1 hi cells are enriched for latentlly infected cells Da Fonesca et al., HIV Reservoir Workshop, Vienna, July 2010 Donor ADonor BDonor C Mock a-PD-1 blocking Ab Isotype control p24 (pg/mL) Chomont et al., Nature Med 2009;15: 893

What is the fate of a latently infected cell? Negative regulators differentiation EM activation Homeostatic proliferation IL-15

role of the adaptive immune response

Inverse relationship between HIV- specific CD4+ T-cells and HIV DNA Martinez et al., J Infect Dis 2001; 191:2053–63 N=66; long term non progressors, no ARV

HLA type influences size and distribution of latently infected cells Descours; Avettand-Fenoel Submitted

Summary  Latency can be established in multiple T-cell subsets  High concentration of latently infected cells in tissue including GI tract and lymphoid tissue  Chemokines and dendritic cells play a key role in establishing latency in resting T-cells  Maintenance of latency can occur by –Homeostatic proliferation (IL-7) –Negative regulators of T-cell activation (PD1)  Adaptive immune response likely important

What is the fate of a latently infected cell? Negative regulators differentiation EM activation Homeostatic proliferation Anti-IL7Anti-PD-1 Auranofin IL-15 Chemokine antagonists vaccination minocycline

Acknowledgements  Department of Medicine, Monash University, Melbourne –Paul Cameron –Suha Saleh –Vanessa Evans –Nitasha Kumar –Ajantha Solomon –Georgina Sallman –Fiona Wightman  Westmead Millenium Research Institute, Sydney –Tony Cunningham –Andrew Harman  VGTI Florida, Port St Lucie, FL –Rafick Sekaly –Elias Haddad –Genevieve Boucher –Nicolas Chomont  Hopital Pitie Salpatriere, Paris –Brigitte Autran –Benjamin Descours